117 related articles for article (PubMed ID: 28781022)
21. Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.
Colomer R; Hall P; Szkultecka-Debek M; Bondi RC; Flinois A; Auziere S; Le Cléac'h JY
Breast Cancer Res Treat; 2018 Feb; 168(1):197-205. PubMed ID: 29170976
[TBL] [Abstract][Full Text] [Related]
22. Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study.
Steger GG; Dominguez A; Dobrovolskaya N; Giotta F; Tubiana-Mathieu N; Pecherstorfer M; Ardizzoia A; Blasinska-Morawiec M; Espinosa E; Villanova G
Clin Breast Cancer; 2018 Feb; 18(1):e41-e47. PubMed ID: 28666812
[TBL] [Abstract][Full Text] [Related]
23. What is the benefit of treatment with multiple lines of chemotherapy for patients with metastatic breast cancer? A retrospective cohort study.
Bakker JL; Wever K; van Waesberghe JH; Beeker A; Meijers-Heijboer H; Konings IR; Verheul HM
Cancer Epidemiol; 2015 Dec; 39(6):848-53. PubMed ID: 26651445
[TBL] [Abstract][Full Text] [Related]
24. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
Vernieri C; Milano M; Mennitto A; Maggi C; Ferrari B; Rinaldi L; Mennitto R; Stefanetti C; Re B; Mariani G; Bianchi G; Capri G; de Braud F
Breast Cancer Res Treat; 2017 Sep; 165(2):365-373. PubMed ID: 28616768
[TBL] [Abstract][Full Text] [Related]
26. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
27. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy.
Rier HN; Jager A; Sleijfer S; van Rosmalen J; Kock MCJM; Levin MD
Breast; 2017 Feb; 31():9-15. PubMed ID: 27810702
[TBL] [Abstract][Full Text] [Related]
28. Palliative Care Interventions and End-of-Life Care for Patients with Metastatic Breast Cancer: A Multicentre Analysis.
Lucchi E; Berger F; Milder M; Commer JM; Morin S; Capodano G; Thomaso M; Fogliarini A; Bremaud N; Henry A; Mastroianni B; Chvetzoff G; Bouleuc C
Oncologist; 2024 May; 29(5):e708-e715. PubMed ID: 38387031
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.
Boudin L; Chabannon C; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Gonçalves A
Eur J Cancer; 2016 Apr; 57():118-26. PubMed ID: 26918737
[TBL] [Abstract][Full Text] [Related]
30. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
[TBL] [Abstract][Full Text] [Related]
32. Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series.
Giannone G; Milani A; Ghisoni E; Genta S; Mittica G; Montemurro F; Valabrega G
Breast; 2018 Apr; 38():160-164. PubMed ID: 29413403
[TBL] [Abstract][Full Text] [Related]
33. Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer.
Mutlu H; Musri FY; Artaç M; Kargi A; Özdogan M; Bozcuk H
J Cancer Res Ther; 2015; 11(2):287-90. PubMed ID: 26148586
[TBL] [Abstract][Full Text] [Related]
34. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
[TBL] [Abstract][Full Text] [Related]
35. Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials.
Thientosapol ES; Tran TT; Della-Fiorentina SA; Adams DH; Chantrill L; Stockler MR; Kiely BE
Intern Med J; 2013 Aug; 43(8):883-8. PubMed ID: 23656187
[TBL] [Abstract][Full Text] [Related]
36. Factors that affect the duration of the interval between the completion of palliative chemotherapy and death.
Hashimoto K; Yonemori K; Katsumata N; Hotchi M; Kouno T; Shimizu C; Tamura K; Ando M; Takeuchi M; Fujiwara Y
Oncologist; 2009 Jul; 14(7):752-9. PubMed ID: 19596665
[TBL] [Abstract][Full Text] [Related]
37. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer.
Botteri E; Sandri MT; Bagnardi V; Munzone E; Zorzino L; Rotmensz N; Casadio C; Cassatella MC; Esposito A; Curigliano G; Salvatici M; Verri E; Adamoli L; Goldhirsch A; Nolè F
Breast Cancer Res Treat; 2010 Jul; 122(1):211-7. PubMed ID: 19967556
[TBL] [Abstract][Full Text] [Related]
38. Aggressiveness of cancer-care near the end-of-life in Korea.
Keam B; Oh DY; Lee SH; Kim DW; Kim MR; Im SA; Kim TY; Bang YJ; Heo DS
Jpn J Clin Oncol; 2008 May; 38(5):381-6. PubMed ID: 18411260
[TBL] [Abstract][Full Text] [Related]
39. Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line?
Tacca O; LeHeurteur M; Durando X; Mouret-Reynier MA; Abrial C; Thivat E; Bayet-Robert M; Penault-Llorca F; Chollet P
Cancer Invest; 2009 Jan; 27(1):81-5. PubMed ID: 19191099
[TBL] [Abstract][Full Text] [Related]
40. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
